exon 21 L858R
Showing 1 - 25 of >10,000
NSCLC, Bevacizumab, EGF-R Positive NSCLC Trial in Tianjin (Bevacizumab, Icotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Mar 2, 2022
Lung Cancer Trial in Guangzhou (Osimertinib, Bevacizumab)
Not yet recruiting
- Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 26, 2021
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)
Recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Combined therapy of anlotinib and aumolertinib
-
Kunming, Yunnan, ChinaFirst Affiliated Hospital of Kunming University
Oct 22, 2023
NSCLC (NSCLC) Trial (Dacomitinib+Anlotinib, Dacomitinib)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Feb 28, 2022
NSCLC, ErbB Receptors Trial in United States (Afatinib)
Completed
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
-
Scottsdale, Arizona
- +9 more
Mar 16, 2020
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- Plasma ctDNA
- FFPE blocks
-
Angers, France
- +35 more
Sep 19, 2023
EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy
Not yet recruiting
- EGF-R Positive Non-Small Cell Lung Cancer
- +4 more
- Stereotactic Body Radiation Therapy SBRT
-
Bogotá, ColombiaCTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
Aug 16, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022
NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Patritumab deruxtecan
- Osimertinib
-
Santa Monica, California
- +13 more
Feb 1, 2023
NSCLC Stage IV, EGFR Gene Mutation Trial in Worldwide (Osimertinib, Stereotactic Body Radiation Therapy (SBRT))
Recruiting
- NSCLC Stage IV
- EGFR Gene Mutation
- Osimertinib
- Stereotactic Body Radiation Therapy (SBRT)
-
Alessandria, Italy
- +15 more
Mar 29, 2022
Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)
Not yet recruiting
- Carcinoma, Non-small-Cell Lung
- Amivantamab
- +3 more
-
Westwood, Kansas
- +47 more
Aug 17, 2022
Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)
Active, not recruiting
- Non Small Cell Lung Cancer
-
Durham, North CarolinaDuke University Medical Center
May 23, 2022
NSCLC (NSCLC) Trial in China (Capmatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
Xiamen, Fujian, China
- +18 more
Jan 27, 2023
PFS Trial in Shanghai (Gefitinib, Bevacizumab Combined With Gefitinib)
Recruiting
- PFS
- Gefitinib
- Bevacizumab Combined With Gefitinib
-
Shanghai, Shanghai, ChinaCancer hospital Fudan University
Jun 10, 2020
Malaria Trial in Oxford (R21/Matrix-M, Rabies vaccine)
Active, not recruiting
- Malaria
- R21/Matrix-M
- Rabies vaccine
-
Oxford, United KingdomCCVTM, University of Oxford, Churchill Hospital
Jan 26, 2022
NSCLC Trial in Worldwide (PF-06747775, Palbociclib, Avelumab)
Terminated
- Non-Small Cell Lung Cancer
- PF-06747775
- +2 more
-
La Jolla, California
- +14 more
May 13, 2021
Double-dose Furmonertinib in Treatment of Slow
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- (no location specified)
Oct 31, 2023
Osimertinib for NSCLC With Uncommon EGFR Mutations
Enrolling by invitation
- Carcinoma, Non-Small-Cell Lung
- Genes, erbB-1
-
Ramat Gan, IsraelSheba Medical Centre
Jun 14, 2022
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)
Not yet recruiting
- Non Small Cell Lung Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Aug 31, 2023
NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100
Not yet recruiting
- Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
- MCLA-129: 1500mg or 2000mg IV Q2W
- Befotertinib: 75 mg or 100 mg Po QD
-
Bengbu, Anhui, China
- +2 more
Aug 28, 2023
Advanced NSCLC Trial in Jinan (almonertinib)
Recruiting
- Advanced Non-small Cell Lung Cancer
-
Jinan, Shandong, ChinaDegan Lu
Sep 12, 2023